Risk factors affecting prognosis in metachronous liver metastases from WHO classification G1 and G2 gastroenteropancreatic neuroendocrine tumors after initial R0 surgical resection

Table 2 Metastatic survival according to age, gender, and tumor characteristics (n = 108)

Characteristics		Median OS (Months)	95% CI	3-year Survival rate	P-value
Age	< 60	32.0	29.7–54.3	24.2%	0.818
Age	≥60	28.0	20.1–46.0	22.3%
Gender	Male	22.8	6.2–39.4	15.4%	0.287
Gender	Female	44.9	18.9–62.9	25.6%
Primary tumor Grade	G1	70.0	40.2–98.1	21.74%	0.0028
Primary tumor Grade	G2	28.0	18.7–36.1	6.25%
Hepatic Tumor Number	Single	44.6	23.3–65.9	23.5%	0.000
Hepatic Tumor Number	Multiple	13.0	9.5–16.6	5.3%
Lymph-node meta	Present	32.0	11.3–52.7	11.3%	0.035
Lymph-node meta	Absent	53.0	10.4–75.6	23.3%
Tumor origin	Pancreas	44.6	17.9–71.3	–	0.273
Tumor origin	GI tract	22.6	12.3–33.0	–
Treatment modalities^a	Local treatment	60.0	–	39.0%	0.009
	Systemic treatment	13.0	–	16.8%
	Combined treatment	27.0	–	25.6%
Longest hepatic tumor diameter	> 4.5 cm	32.0	12.1–51.8		0.343
Longest hepatic tumor diameter	≤4.5 cm	39.7	29.9–71.4

^aThe treatment modality was the treatment dealing with the hepatic metastatic masses

ISSN: 1471-2407